A CLINICAL STUDY OF FORTEPREN PREPARATION

A CLINICAL STUDY OF FORTEPREN PREPARATION

A CLINICAL STUDY OF FORTEPREN PREPARATION
IDU does not shorten the natural course of recurrent HSL. On the other hand, treatment of HSV people with both HIV and HSV can reduce HIV viral load. HSV-1, VZV, and PRV induced very different substrate profiles that were US3/ORF66 kinase dependent. After a 10-day acyclovir course (400 mg x 3 times a day) for removing the acute phase, 4 groups of 10 individuals were formed: 1–5 ml (20 mg) of fortepren i/m once at day 13 ± 2 after the start of the study after the completion of the treatment of the acute phase of the disease; 2–5 ml (20 mg) fortepren i/m 3 times at an interval of 21 days; 3–2 ml (8 mg) fortepren i/m 3 times at an interval of 21 days; 4 (control)–5 ml of placebo i/m at remission stage 3 times at an interval of 21 days. Increase of the duration of inter-recurrence period, decrease of the severity of the recurrences, state of skin and mucous damage elements, improvements of immunologic parameters were considered during effectiveness evaluation. You can get genital herpes through genital-genital contact or genital-oral contact with herpes on penile tip swelling who has herpes infection. However, purified VZV ORF66 kinase did not phosphorylate matrin 3 in vitro, suggesting that additional cellular factors were required.

The frequency of recurrences in the control group was 3.84 ± 0.10, that was higher than the parameters in all the experimental groups. A significant reduction of the rash area was noted in group 3, moreover, a redution of frequency of detection of clinical manifestations of genital herpes in the form of vesicle elements after treatment in groups 2 (p = 0.02) and 3 (p = 0.005) was found. We’ve had several patients who presented with malaise, tingling and pain along the first division of the fifth cranial nerve . Considerable interest in their roles and functions has developed, because they influence multiple cellular processes by controlling the phosphorylation of both cellular and viral proteins. Intramuscular administration of fortepren preparation was established to result in the increase of titers of leukocyte virus-induced interferon for the whole duration of treatment. CONCLUSION An intramuscular dose of 2 ml (8 mg) at recurrence stage 3 times at an interval of 21 days after the completion of the 10-day base course of treatment of the acute phase of chronical recurrent herpes virus infection of genital localization using acyclovir was accepted as an optimal dosage regimen. Analysis of the obtained results has shown an acceptable safety profile and a good level of tolerance for fortepren preparation.

You may also like